Specialty pharmaceutical company focused on developing and commercializing treatments for chronic pain.
Collegium Pharmaceutical, Inc. is a specialized pharmaceutical company dedicated to advancing medications tailored for effective pain management. At the core of its product portfolio is Xtampza ER, an abuse-deterrent formulation of extended-release oxycodone designed to provide consistent pain relief while deterring misuse. Additionally, the company offers Nucynta ER and Nucynta IR, which are formulations of tapentadol, catering to both extended-release and immediate-release needs for pain management.
Founded in 2002 and headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical, Inc. originally operated under the name Collegium Pharmaceuticals, Inc. before rebranding in October 2003. Since its inception, the company has been dedicated to addressing the complex challenges associated with pain management through innovative pharmaceutical solutions.
Collegium Pharmaceutical, Inc. prides itself on its commitment to enhancing patient outcomes by providing healthcare professionals with safe and effective treatment options. The company's strategic focus on abuse-deterrent formulations underscores its dedication to combating opioid misuse while ensuring that patients with chronic pain receive the care they need.
With a robust pipeline and a strong foundation in pharmaceutical innovation, Collegium Pharmaceutical, Inc. continues to lead the way in developing and commercializing advanced pain management therapies that prioritize patient safety and efficacy.